Patents by Inventor Leo Chylack

Leo Chylack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080088795
    Abstract: A system for performing quasi-elastic light scattering and fluorescent ligand scanning on a subject's eye includes a light source configured to transmit light toward the subject's eye, a lens configured to focus light sent from the source and scattered by the subject's eye, a measurement reflector disposed to receive at least a portion of the focused light and configured to reflect a first portion of the received light, a camera configured and disposed to receive the first portion of the received light and configured to provide indicia of an image corresponding to the first portion of the received light, and a processor coupled to the camera and configured to analyze intensities of light in the image to determine a location of a reference point corresponding to an interface of a portion of the eye.
    Type: Application
    Filed: April 11, 2007
    Publication date: April 17, 2008
    Inventors: Lee Goldstein, Norman Ford, Leo Chylack, Paul Hartung, Marc Friedman, Evan Sherr, Stephen Fantone
  • Publication number: 20070038127
    Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.
    Type: Application
    Filed: August 28, 2006
    Publication date: February 15, 2007
    Inventors: Lee Goldstein, Leo Chylack, Ashley Bush
  • Publication number: 20050095653
    Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
    Type: Application
    Filed: December 15, 2004
    Publication date: May 5, 2005
    Inventors: Lee Goldstein, Leo Chylack